05:06 PM EDT, 08/13/2024 (MT Newswires) -- Fate Therapeutics ( FATE ) reported a Q2 loss late Tuesday of $0.33 per diluted share, narrowing from a loss of $0.54 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.46 per share.

Revenue for the quarter ended June 30 was $6.8 million, up from $933,000 a year earlier.

Analysts surveyed by Capital IQ expected $1.6 million.

Shares of the company were up 3.3% in after-hours activity.

Price: 3.4500, Change: +0.11, Percent Change: +3.29